Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

MLA

Ludovini, Vienna, et al. “Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations Are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 6, no. 4, Apr. 2011, pp. 707–15. EBSCOhost, https://doi.org/10.1097/JTO.0b013e31820a3a6b.

APA

Ludovini, V., Bianconi, F., Pistola, L., Chiari, R., Minotti, V., Colella, R., Giuffrida, D., Tofanetti, F. R., Siggillino, A., Flacco, A., Baldelli, E., Iacono, D., Mameli, M. G., Cavaliere, A., & Crinò, L. (2011). Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 6(4), 707–715. https://doi.org/10.1097/JTO.0b013e31820a3a6b

Chicago

Ludovini, Vienna, Fortunato Bianconi, Lorenza Pistola, Rita Chiari, Vincenzo Minotti, Renato Colella, Dario Giuffrida, et al. 2011. “Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations Are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 6 (4): 707–15. doi:10.1097/JTO.0b013e31820a3a6b.